AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3546936 — intervention group
Group type: EXPERIMENTAL
Intervention: PSF of 4.5 kHz
Number of subjects: 242
Study 3546936 — intervention group
Group type: EXPERIMENTAL
Intervention: PSF of 5.0 kHz
Number of subjects: 242
Study 3546936 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis of PSF
Number of subjects: 242
Study 3546936 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear regression analysis of PSF
Number of subjects: 242
Study 31595830 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining social scenarios with positive outcomes
Number of subjects: 197
Study 31595830 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining social scenarios with negative outcomes
Number of subjects: 197
Study 31595830 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining non-social scenarios with positive outcomes
Number of subjects: 197
Study 31595830 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining non-social scenarios with negative outcomes
Number of subjects: 197
Study 30962136 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 136
Study 30962136 — intervention group
Group type: COMPARATOR
Intervention: Open liver resection
Number of subjects: 136
Study 28639542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate MDPI (100 or 200 μg)
Number of subjects: 728
Study 28639542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol MDPI (100 μg/12.5 μg or 200 μg/12.5 μg)
Number of subjects: 728
Study 28639542 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDPI
Number of subjects: 728
Study 28639542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol MDPI (100 μg/12.5 μg)
Number of subjects: 728
Study 26520220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 30
Study 26520220 — intervention group
Group type: COMPARATOR
Intervention: Anxiety Management (Control)
Number of subjects: 30
Study 22766525 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg
Number of subjects: 77
Study 22766525 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 15 mg
Number of subjects: 77
Study 22766525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 21729145 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC‐treated T‐shirts (28 pieces for 4 weeks)
Number of subjects: 40
Study 21729145 — intervention group
Group type: COMPARATOR
Intervention: Non‐treated T‐shirts
Number of subjects: 40
Study 19546756 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (repeat courses)
Number of subjects: 251
Study 19546756 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (at least four repeat courses)
Number of subjects: 251
Study 19546756 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (1-3 repeat courses)
Number of subjects: 251
Study 19546756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 17127775 — intervention group
Group type: EXPERIMENTAL
Intervention: PriorixA
Number of subjects: 60
Study 17127775 — intervention group
Group type: COMPARATOR
Intervention: M-M-R IIA
Number of subjects: 60
Study 15580380 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents (Postgraduate year two)
Number of subjects: 152
Study 15580380 — intervention group
Group type: COMPARATOR
Intervention: Attending surgeons
Number of subjects: 152
Study 15580380 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents and attending surgeons
Number of subjects: 152
Study 11395039 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble P-selectin levels in patients with unstable coronary artery disease (n=44)
Number of subjects: 76
Study 11395039 — intervention group
Group type: COMPARATOR
Intervention: Soluble P-selectin levels in patients with stable atherosclerotic disease (n=32)
Number of subjects: 76
Study 11395039 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma level of soluble P-selectin as a predictor of unstable coronary syndrome
Number of subjects: 76
Study 11395039 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of soluble P-selectin with alpha-tocopherol levels
Number of subjects: 76
Study 9571379 — intervention group
Group type: EXPERIMENTAL
Intervention: Persons with paraplegia
Number of subjects: 677
Study 9571379 — intervention group
Group type: COMPARATOR
Intervention: Non-disabled persons
Number of subjects: 677
Study 7826564 — intervention group
Group type: EXPERIMENTAL
Intervention: Monatepil monotherapy (30 mg/day initially, titrated to 60 mg/day)
Number of subjects: 0
Study 7826564 — intervention group
Group type: EXPERIMENTAL
Intervention: Monatepil in combination with ACE inhibitors (15 mg/day initially, titrated to 60 mg/day)
Number of subjects: 0
Study 7826564 — intervention group
Group type: EXPERIMENTAL
Intervention: Monatepil in combination with beta-blockers (15 mg/day initially, titrated to 60 mg/day)
Number of subjects: 0
Study 7826564 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during 4-week control period)
Number of subjects: 0
Study 3417080 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at 19.00 h
Number of subjects: 14
Study 3417080 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at 22.00 h
Number of subjects: 14
Study 3417080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29566729 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hyperoxygenation (100% oxygen supplied to the mother by a non-rebreathing mask until delivery)
Number of subjects: 116
Study 29566729 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hyperoxygenation
Number of subjects: 116
Study 29566729 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control group)
Number of subjects: 116
Study 29566729 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 116
Study 27424564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel technique using collagen matrix (CM)
Number of subjects: 28
Study 27424564 — intervention group
Group type: COMPARATOR
Intervention: Tunnel technique using connective tissue graft (CTG)
Number of subjects: 28
Study 25122130 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM) intervention
Number of subjects: 184
Study 25122130 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) intervention
Number of subjects: 184
Study 25122130 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 23882458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel
Number of subjects: 80
Study 23882458 — intervention group
Group type: COMPARATOR
Intervention: dry dressing (placebo)
Number of subjects: 80
Study 22029737 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensed video‐based individual coaching sessions (15 min.) supported by a manual and a DVD.
Number of subjects: 40
Study 22029737 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (not receiving the intervention).
Number of subjects: 40
Study 19219666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 106
Study 19219666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-SR
Number of subjects: 106
Study 19219666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 17007850 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion sonohysterography (SIS)
Number of subjects: 1009
Study 12920686 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith AAA Endovascular Graft
Number of subjects: 352
Study 12920686 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical repair
Number of subjects: 352
Study 10963999 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom intervention with education program on use of female and male condoms and STDs.
Number of subjects: 1929
Study 10963999 — intervention group
Group type: COMPARATOR
Intervention: Control communities received information on use of male condoms.
Number of subjects: 1929
Study 8817802 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2285642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 100
Study 2285642 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 100
Study 7015020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin (antibiotic)
Number of subjects: 211
Study 31092196 — intervention group
Group type: EXPERIMENTAL
Intervention: RB stock solution 10 mg/ml (Group 1)
Number of subjects: 39
Study 31092196 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-fold dilution 5 mg/ml (Group 2)
Number of subjects: 39
Study 31092196 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-fold dilution 3.3 mg/ml (Group 3)
Number of subjects: 39
Study 27735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified consent form
Number of subjects: 0
Study 27735922 — intervention group
Group type: COMPARATOR
Intervention: Traditional consent form
Number of subjects: 0
Study 27735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Review/retest intervention
Number of subjects: 0
Study 27735922 — intervention group
Group type: COMPARATOR
Intervention: Lowest education group
Number of subjects: 0
Study 27735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quiz scores
Number of subjects: 0
Study 25820113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization of ropivacaine 150 mg before surgery
Number of subjects: 140
Study 25820113 — intervention group
Group type: COMPARATOR
Intervention: Instillation of ropivacaine 150 mg before surgery
Number of subjects: 140
Study 24791343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 156
Study 24791343 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 1% gel
Number of subjects: 156
Study 21806591 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesic protocol (n=47)
Number of subjects: 92
Study 21806591 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=45)
Number of subjects: 92
Study 21806591 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 19204205 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel, doxorubicin, and cyclophosphamide (TAC)
Number of subjects: 1350
Study 19204205 — intervention group
Group type: COMPARATOR
Intervention: fluorouracil, doxorubicin, and cyclophosphamide (FAC)
Number of subjects: 1350
Study 19204205 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 1350
Study 16707961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy with Rhenium liquid-filled angioplasty balloon system
Number of subjects: 165
Study 16707961 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 165
Study 16707961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy
Number of subjects: 165
Study 15343588 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide-primed arm (subcutaneous exenatide starting at 0.02 micro g/kg TID, increasing every 3 days for 35 days)
Number of subjects: 123
Study 15343588 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide-primed arm
Number of subjects: 123
Study 15343588 — intervention group
Group type: COMPARATOR
Intervention: Exenatide-naive arm (placebo TID for 35 days)
Number of subjects: 123
Study 11156782 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intraarterial/intravenous thrombolysis with 50 mg actilyse (maximal dose, 0.7 mg/kg)
Number of subjects: 45
Study 11156782 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 45
Study 11156782 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis group
Number of subjects: 45
Study 11156782 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 9797806 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 9797806 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 9797806 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multimodal therapy (surgery and/or radiotherapy with chemotherapy)
Number of subjects: 0
Study 7639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural butorphanol 30 micrograms/kg
Number of subjects: 60
Study 7639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous butorphanol 30 micrograms/kg
Number of subjects: 60
Study 7639376 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 60 micrograms/kg
Number of subjects: 60
Study 3281411 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 microgram alphacalcidol
Number of subjects: 65
Study 28919502 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory foam pad (group A)
Number of subjects: 43
Study 28919502 — intervention group
Group type: COMPARATOR
Intervention: Bean bag with shoulder braces (group B)
Number of subjects: 43
Study 27535349 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8000
Study 27535349 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/VKA
Number of subjects: 8000
Study 24656286 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment at baseline pump speed and at each 1,000-rpm interval from 8,000 rpm to 11,000 rpm
Number of subjects: 52
Study 23036149 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted tailored implementation intervention of a clinical decision support system including interactive education, reminders, monitoring, feedback and leadership.
Number of subjects: 464
Study 23036149 — intervention group
Group type: COMPARATOR
Intervention: Hard-copy of the pressure ulcer prevention protocol supported by standardized 30 min group lecture.
Number of subjects: 464
Study 20189976 — intervention group
Group type: EXPERIMENTAL
Intervention: FCSI-9
Number of subjects: 391
Study 18437173 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 0
Study 18437173 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen ablation therapy
Number of subjects: 0
Study 18437173 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapies (kinase inhibitors, antisense oligonucleotides, inhibitors of heat-shock proteins)
Number of subjects: 0
Study 18437173 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting ETS transcription factors or TMPRSS2-ETS gene fusion
Number of subjects: 0
Study 16088404 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine, vincristine + prednisone (BOP)
Number of subjects: 164
Study 16088404 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine + prednisone (COP)
Number of subjects: 164
Study 16088404 — intervention group
Group type: EXPERIMENTAL
Intervention: BOP in responders
Number of subjects: 164
Study 16088404 — intervention group
Group type: EXPERIMENTAL
Intervention: BOP in responders not receiving interferon maintenance therapy
Number of subjects: 164
Study 16088404 — intervention group
Group type: COMPARATOR
Intervention: COP
Number of subjects: 164
Study 16088404 — intervention group
Group type: EXPERIMENTAL
Intervention: BOP and COP
Number of subjects: 164
Study 12925153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (OA-R)
Number of subjects: 206
Study 12925153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (OA-P)
Number of subjects: 206
Study 11783329 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinyikang Oral Liquid (XYK)
Number of subjects: 92
Study 11783329 — intervention group
Group type: COMPARATOR
Intervention: Qidong Yixin oral liquid
Number of subjects: 92
Study 8981292 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50 mg daily
Number of subjects: 6602
Study 8981292 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release dipyridamole 400 mg daily
Number of subjects: 6602
Study 8981292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ASA and dipyridamole
Number of subjects: 6602
Study 8981292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6602
Study 8266157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine spray
Number of subjects: 55
Study 8266157 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine gel
Number of subjects: 55
Study 3541948 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunisation therapy
Number of subjects: 40
Study 31421110 — intervention group
Group type: EXPERIMENTAL
Intervention: Orvepitant 30 mg once daily for 4 weeks
Number of subjects: 13
Study 28886575 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy with normative feedback
Number of subjects: 252
Study 26358533 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention (single home visit and 3-4 follow-up phone calls by a nurse over 90 days)
Number of subjects: 67
Study 26358533 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study 24290415 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of miglitol (100 mg)
Number of subjects: 40
Study 24290415 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of miglitol (100 mg)
Number of subjects: 40
Study 23739513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (monotherapy, daily dosage 0.1 ml/kg, in the morning hours, on each other day, i.m., 30 injections in total) during 2 months
Number of subjects: 60
Study 23739513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacotherapy)
Number of subjects: 60
Study 23739513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 60
Study 20978446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus matuzumab (800 mg weekly)
Number of subjects: 148
Study 20978446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus matuzumab (1600 mg every 3 weeks)
Number of subjects: 148
Study 20978446 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed alone
Number of subjects: 148
Study 17900252 — intervention group
Group type: EXPERIMENTAL
Intervention: ARVD/C patients
Number of subjects: 42
Study 17900252 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 42
Study 16884981 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine
Number of subjects: 44
Study 16884981 — intervention group
Group type: COMPARATOR
Intervention: Propofol-ketamine
Number of subjects: 44
Study 12844130 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 300 pmol/min vasopressin administered by the intrabrachial route
Number of subjects: 12
Study 12844130 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 pmol/min vasopressin administered by the intrabrachial route
Number of subjects: 12
Study 12844130 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged continuous infusion of vasopressin
Number of subjects: 12
Study 12844130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin with nitric oxide clamp (4 micromol/min L‐N(G)‐monomethylarginine and 0.3 to 0.8 nmol/min sodium nitroprusside)
Number of subjects: 12
Study 11082411 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia
Number of subjects: 1732
Study 11082411 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 1732
Study 11082411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal perioperative outcomes
Number of subjects: 1732
Study 8803508 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially active recovery (20 min of pedalling at 40% VO2max followed by 40 min of seated rest)
Number of subjects: 14
Study 8803508 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (20 min seated on cycle ergometer followed by 40 min more of seated rest)
Number of subjects: 14
Study 8803508 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise intensity
Number of subjects: 14
Study 8803508 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max
Number of subjects: 14
Study 8803508 — intervention group
Group type: COMPARATOR
Intervention: Partially active recovery vs passive recovery
Number of subjects: 14
Study 1307878 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-based systems with complex clinical algorithms tailored to specific patient conditions.
Number of subjects: 0
Study 1307878 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive and noninvasive monitoring systems.
Number of subjects: 0
Study 6401416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (CS)
Number of subjects: 10
Study 6401416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31489645 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm allocating ICD-10-AM codes into 'probable' or 'possible' causes of GIB
Number of subjects: 716
Study 31489645 — intervention group
Group type: COMPARATOR
Intervention: Source medical records validation
Number of subjects: 716
Study 29502984 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily at bedtime
Number of subjects: 595
Study 26179569 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program lifestyle intervention (n = 30) consisting of 12 bi‐weekly core sessions and six monthly post‐core sessions
Number of subjects: 60
Study 26179569 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (n = 30) consisting of quarterly mailing of diabetes prevention information
Number of subjects: 60
Study 24559487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise training on a bicycle ergometer, 18 sessions, three times a week
Number of subjects: 44
Study 24559487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise training
Number of subjects: 44
Study 22869325 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy goal-setting condition
Number of subjects: 98
Study 22869325 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult goal-setting condition
Number of subjects: 98
Study 22869325 — intervention group
Group type: COMPARATOR
Intervention: Do-your-best goal-setting condition (Control)
Number of subjects: 98
Study 20119647 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX3 levels measured daily for 7 days and then at days 9, 11, 13, 18, 23, and 28.
Number of subjects: 90
Study 20119647 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 PTX3 levels in septic shock patients.
Number of subjects: 90